CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 380 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $85,759,995 | -52.5% | 1,587,854 | 0.0% | 6.45% | -42.4% |
Q1 2024 | $180,406,122 | +81.5% | 1,587,854 | 0.0% | 11.20% | +69.0% |
Q4 2023 | $99,399,660 | +37.9% | 1,587,854 | 0.0% | 6.62% | +19.0% |
Q3 2023 | $72,072,693 | -19.1% | 1,587,854 | 0.0% | 5.57% | -18.2% |
Q2 2023 | $89,142,124 | +24.1% | 1,587,854 | 0.0% | 6.80% | +37.1% |
Q1 2023 | $71,818,636 | +11.3% | 1,587,854 | 0.0% | 4.96% | +36.9% |
Q4 2022 | $64,546,265 | -37.9% | 1,587,854 | -0.1% | 3.63% | -30.1% |
Q3 2022 | $103,907,000 | +7.5% | 1,590,002 | 0.0% | 5.19% | +4.5% |
Q2 2022 | $96,624,000 | -73.6% | 1,590,002 | 0.0% | 4.96% | -53.0% |
Q1 2022 | $365,593,000 | +203.4% | 1,590,002 | 0.0% | 10.56% | +333.7% |
Q4 2021 | $120,490,000 | -32.3% | 1,590,002 | 0.0% | 2.44% | +15.2% |
Q3 2021 | $177,969,000 | -30.9% | 1,590,002 | 0.0% | 2.11% | -37.0% |
Q2 2021 | $257,405,000 | +32.9% | 1,590,002 | 0.0% | 3.35% | -22.9% |
Q1 2021 | $193,742,000 | -20.4% | 1,590,002 | 0.0% | 4.35% | -32.3% |
Q4 2020 | $243,445,000 | +83.1% | 1,590,002 | 0.0% | 6.43% | +14.2% |
Q3 2020 | $132,988,000 | -13.4% | 1,590,002 | -23.9% | 5.63% | -8.8% |
Q2 2020 | $153,644,000 | +73.3% | 2,090,678 | 0.0% | 6.18% | +33.3% |
Q1 2020 | $88,666,000 | -30.4% | 2,090,678 | 0.0% | 4.63% | -23.1% |
Q4 2019 | $127,322,000 | +48.6% | 2,090,678 | 0.0% | 6.02% | -15.1% |
Q3 2019 | $85,697,000 | -13.0% | 2,090,678 | 0.0% | 7.10% | +2.9% |
Q2 2019 | $98,471,000 | +31.9% | 2,090,678 | 0.0% | 6.90% | +77.9% |
Q1 2019 | $74,679,000 | +25.0% | 2,090,678 | 0.0% | 3.88% | +63.7% |
Q4 2018 | $59,731,000 | -35.6% | 2,090,678 | 0.0% | 2.37% | -40.8% |
Q3 2018 | $92,722,000 | -24.5% | 2,090,678 | 0.0% | 4.00% | -30.5% |
Q2 2018 | $122,848,000 | -22.9% | 2,090,678 | -40.0% | 5.76% | -18.8% |
Q1 2018 | $159,275,000 | +110.6% | 3,484,464 | +8.2% | 7.08% | +126.1% |
Q4 2017 | $75,623,000 | +31.4% | 3,220,728 | 0.0% | 3.13% | +55.4% |
Q3 2017 | $57,554,000 | +11.5% | 3,220,728 | 0.0% | 2.02% | +7.4% |
Q2 2017 | $51,596,000 | -26.4% | 3,220,728 | 0.0% | 1.88% | -23.0% |
Q1 2017 | $70,115,000 | +7.5% | 3,220,728 | 0.0% | 2.44% | -6.0% |
Q4 2016 | $65,252,000 | – | 3,220,728 | – | 2.60% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |